H.C. Wainwright Reaffirms Their Buy Rating on Xeris Pharmaceuticals (XERS)

In a report released today, Oren Livnat from H.C. Wainwright reiterated a Buy rating on Xeris Pharmaceuticals (XERSResearch Report), with a price target of $6.00. The company’s shares closed yesterday at $1.93.

According to TipRanks, Livnat is an analyst with an average return of -0.5% and a 42.68% success rate. Livnat covers the Healthcare sector, focusing on stocks such as Avadel Pharmaceuticals, Otonomy, and Collegium Pharmaceutical.

Currently, the analyst consensus on Xeris Pharmaceuticals is a Strong Buy with an average price target of $6.00.

See today’s best-performing stocks on TipRanks >>

Based on Xeris Pharmaceuticals’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $22.07 million and a GAAP net loss of $33.71 million. In comparison, last year the company earned a revenue of $8.2 million and had a GAAP net loss of $18.41 million

Based on the recent corporate insider activity of 29 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of XERS in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Xeris Pharmaceuticals, a pharmaceutical company, which develops and commercializes ready-to-use, liquid-stable injectables. It offers XeriSol™ and XeriJect™ formulation technologies. The company was founded by Steven Prestrelski and John Kinzell in 2005 and is headquartered in Austin, TX.

Read More on XERS:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More